Workshop on biosimilars

EventCorporateBiosimilars

French is available via eTranslation, the European Commission's machine translation service.

Translate to French | Important information about machine translation

Date

Jeudi, 31 octobre 2013, Journée Entière

Emplacement

European Medicines Agency, Amsterdam, the Netherlands

The workshop is intended to discuss the draft guideline on similar biological medical products, the draft guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, and the draft guideline on similar biological medical products containing biotechnology-derived proteins as active substance: quality issues. Registration closed.

Documents

Agenda - Workshop on biosimilars

Reference Number: EMA/473908/2013

English (EN) (74.69 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

List of participants - Workshop on biosimilars

Reference Number: EMA/681299/2013

English (EN) (143.9 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Draft revised guideline on similar biological medicinal products: Relevant changes (Martina Weise)

English (EN) (234.06 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - EBG’s comments on the draft revised guideline on similar biological medicinal products (Karl Heinz Emmert)

English (EN) (1.09 Mo - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Guideline on similar biological medicinal products: Overarching guideline

English (EN) (734.59 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Guideline on similar biological medicinal products containing biotechnologically-derived proteins as active substances: quality issues (Niklas Ekman)

English (EN) (159.22 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - EGA’s perspective on the draft quality guideline (Joerg Windisch)

English (EN) (922.36 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Quality issues

English (EN) (656.89 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (Niklas Ekman)

English (EN) (309.73 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (Hans-Karl Heim)

English (EN) (117.28 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Guideline on Similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues (Pekka Kurki)

English (EN) (360.9 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - EBG’s perspective on the draft guideline on the non-clinical/clinical issues (Mark McCamish)

English (EN) (1.18 Mo - PDF)

Première publication: Dernière mise à jour:
Voir

Presentation - Nonclinical and clinical considerations

English (EN) (571.74 Ko - PDF)

Première publication: Dernière mise à jour:
Voir

Multimedia

Share this page